Investor Presentation
April 2019
Investor Presentation April 2019 Safe Harbor Statement The - - PowerPoint PPT Presentation
Investor Presentation April 2019 Safe Harbor Statement The offering to which this presentation (the "Presentation") relates will be made pursuant to an offering Forward-looking information contained in this Presentation is based on
April 2019
2
The offering to which this presentation (the "Presentation") relates will be made pursuant to an offering
incorporated by reference therein for more complete information. This Presentation shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. The securities discussed in this Presentation have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and are being offered only to qualified institutional buyers as defined in Rule 144A under the Securities Act or outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act. The securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. This Presentation about Aphria Inc.’s (“Aphria”) activities current as of April 15, 2019. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. These should be considered, with or without professional advice, when deciding if an investment is appropriate. The information contained in this Presentation is derived solely from management of Aphria and
to contain all the information that an investor may desire to have in evaluating whether or not to make an investment in Aphria. The information has not been independently verified and is subject to material updating, revision and further amendment, and is qualified entirely by reference to Aphria’s publicly disclosed information. No representation or warranty, express or implied, is made or given by or on behalf of Aphria or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. Aphria does not undertake or agree to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become
than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorized. The information and opinions contained in this Presentation are provided as at the date of this Presentation. The contents of this Presentation are not to be construed as legal, financial or tax advice. Each prospective investor should contact his, her or its own legal adviser, independent financial adviser or tax adviser for legal, financial
Certain statements in this Presentation may constitute forward-looking information, including future-
Forward-looking information may relate to Aphria’s future outlook and anticipated events or results and may include statements regarding Aphria’s financial results, future financial position, expected growth
plans, objectives, potential synergies, industry trends and growth opportunities. Often but not always, forward-looking information can be identified by the use of words such as “anticipate”, “believe”, “expect”, “project”, “estimate”, “likely”, “intend”, “should”, “could”, “may”, “might”, “target”, “plan” and other similar expressions or variations (including negative variations) of such words and phrases. Forward-looking information contained in this Presentation is based on certain assumptions regarding expected growth, results of operations, performance, industry trends and growth opportunities. While management considers these assumptions to be reasonable, based on information available, they may prove to be incorrect. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aphria to be materially different from any future lts, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors include, but are not limited to risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations, and the other risks discussed under the heading “Industry trends and risks” in Aphria’s Management’s Discussion & Analysis dated April 15, 2019. The foregoing factors are not intended to be exhaustive. Although Aphria has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are made as of the date hereof and Aphria and its directors, officers and employees disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, you should not place undue reliance on forward-looking statements due to the inherent uncertainty therein. All forward-looking information is expressly qualified in its entirety by this cautionary statement. Forward-looking information and other information contained herein concerning management’s general expectations concerning the marijuana industry are based on estimates prepared by management using data from publicly available industry sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which management believes to be reasonable. However, this data is inherently imprecise, although generally indicative of relative market positions, market shares and performance characteristics. While management is not aware of any misstatements regarding any industry data presented herein, industry data is subject to change based on various factors. This Presentation may not be reproduced, further distributed or published in whole or in part by any
distributed in any other jurisdiction which prohibits the same except in compliance with applicable
Recipients are required to inform themselves of, and comply with, all such restrictions or prohibitions and Aphria does not accept liability to any person in relation thereto.
Led by our passion for customers and consumers, Aphria’s mission is to be the premier global cannabis company through an unrelenting commitment to our people, product quality and innovation. Aphria’s vision is to be the best performing cannabis company globally, providing investors with access to one of the most accretive cannabis opportunities around the world.
4
Differentiated Global Cannabis Leader
Strong Brand Positioning
1
Extensive Distribution Model in Canada
2
Product Innovation
3
Industrial Scale Cultivation and Automation
4
Medical-Use Leadership
5
Strategic Global Platform
6
5
Adult-Use and Medical Medical only Adult-Use and Medical (U.S.) Medical only (U.S.) Estimated global cannabis market by 2025(1)
$150B
Estimated Canada market for cannabis by 2024(2)
$9B
Adult-Use cannabis
$6B
Medical cannabis
$3B
(1) Source: Grand View Research. (2) Source: Eight Capital Research.
Adult-Use cannabis
$50B
Medical cannabis
$100B
In US dollars
6
Aphria is at the Forefront of R&D Aimed at Disrupting New Industries (e.g. Wellness)
Current Segment
Medical
Consumer Profile
safety are critical
Sales Channels
Example Products
Future Segment
Wellness
Consumer Profile
enhancement to wellness regime
Sales Channels
wellness retreats) Example Products: Cannabinoid focus is CBD (cannabis or hemp derived)
(nutrition, enhancement and recovery)
cosmetics
Current Segment
Adult-Use
Consumer Profile
Sales Channels
Example Products
(shatter, wax, resin)
beverages
(1) Pharmacy only applicable outside of Canada.
7
Thoughtful Research Process Extensive year-long and three-phased research process identified key consumer segments to optimize brand positioning
Each of Our Brands Has Been Created to Delight Distinct Segments of Consumers, From First- Timers to the Most Experienced Users and Those in Between
Our Brands are Designed to Target Most Profitable Customer Segments We leverage our data and consumer insights to design our in-house and licensed brands in
profitable consumer segments
Value ($) Mainstream ($$) Premium ($$$) Enthusiasts Passive Risk Takers Relaxers Novices Cultivated
8
pharmacies in Canada
sales channel (Direct to Consumers)
Canadian province and the Yukon Territory
99.8% of Canadians
and spirits distributor
(subsidiary) is a national sales broker for legalized adult-use cannabis
partnership
across Canada and potentially benefit from
(Southern Glazer operates in 44 states plus the District
Caribbean
Adult-Use Medical
through telephone and e-commerce
9
(1) When permitted by law.
Leading Producer of High Quality Flower Allows Us to Deliver Derivative Products at Superior Margins Partners In R&D And Analysis Clinical Research & University Partners Infrastructure and Partnerships for Category Must Haves(1) Partnership to Create and Develop Tongue Strips Medical Delivery Systems License Agreement to Develop Cannabis Patches Edibles Softgels Cosmetics Beverages Vapes Concentrates In-House Extraction Centre of Excellence VERVE DYNAMICS specializes in innovative and proprietary technologies for the nutraceutical and phyto-extraction Acquisition of German Pharmaceutical Distributor
10
(1) These figures are considered forward-looking information and are based on the Company’s experience in growing cannabis, and data available concerning the wide variety of strains under the growing conditions maintained at its facilities. Material assumptions to derive capacity at full completion include, but are not limited to: the number of plants expected to occupy each facility, the number of harvest cycles and average yield per harvest cycle per year for the strains expected to be grown at each facility.Subject to Health Canada approval. (2) 800,000 sq. ft. was approved by Health Canada in March 2019, the Company anticipates full crop rotation in May 2019. The current capacity cannot be reached until the Company is in full crop rotation. (3) Subject to Health Canada approval. (4) Medical cultivation license will no longer be provisional provided no opposition arises on or before April 16th, 2019.
Fully Licensed(2)
Facility Type
Aphria One Aphria Diamond Broken Coast
110,000 kg/yr cultivation(2) NA 5,000 kg/year cultivation Greenhouse 1,100,000
4,500
Current Size
Awaiting Approval License Expansion Under Way
Current Capacity(1) Expected Capacity(1) License Status
110,000 kg/yr cultivation 5,000 kg/year cultivation 140,000 kg/year cultivation 1,300,000
Greenhouse Indoor Indoor NA Conditionally Awarded(4)
Aphria Deutschland
65,000
7,000 kg/yr cultivation Outdoor 17,000 kg/yr cultivation License Approved
Jamaica
150,000
17,000 kg/yr cultivation
255,000 kg Combined Annual Canadian Production(3)
One Of The Largest Cultivation Footprints In The Industry
11
Currently Implemented Automation Processes Part IV Part V Cutting-Edge Technology
Cutting Plants Transferring Plants De-budding Process Trimming Process Waste Disposal Bud Distribution Transplanting Cuttings Growth Cycle Evaluation Plant Quality Testing Nutrient Supply Monitoring Growth Cycle Transporting Plants
Bringing Industrial Horticulture Technology Into the Cultivation of Cannabis Within a Greenhouse
12
Aphria is Committed to Responsible Drug Practices, Evidence-Based Treatment and Advancing Cannabis Science
Partner Country Aphria Contribution Indication
Canada Supplying dried flower and cannabis oil products Chronic cancer-related pain Australia Producing and supplying high-yield cannabis extracts Intractable pain in oncology patients Australia Supplying cannabis oil Chronic pain in cats and dogs Argentina Rideau CBD oil Refractory epilepsy in children
13
Aphria Has Invested in Building a Strategic Presence in More than 10 Countries Well-Positioned to Capitalize on Global Cannabis Demand Led by Medical-Use Markets Foothold in the Largest Cannabis Ready Markets
(1) Medical cultivation license in Germany will no longer be provisional provided no opposition arises on or before April 16th, 2019. (2) Signed LOI for exclusive supply agreement.
Canada Germany(1) Colombia Argentina Paraguay (2) Lesotho Malta Australia Denmark Italy Jamaica
Distribution Medical License / Cultivation Research Partnership Medical and Adult-Use License / Processing
14
Awarded Provisional(1) Medical Cannabis Cultivation License by the German Federal Institute of Drugs and Medical Devices
Schöneberg Hospital(2)
Demand Supply Distribution
cultivate cannabis in Germany(1)
to approximately 13,000 active pharmacy accounts
(1) Medical cultivation license will no longer be provisional provided no opposition arises on or before April 16th, 2019. (2) Obtained 25.1% ownership stake in Berlin-based Schöneberg Hospital.
16
Net Revenue $73,582 $21,668 $10,267 Revenue from Cannabis Produced $17,862 $22,738 $10,267 Distribution Revenue $57,599 $1,146 NA Other Revenue $545 $640 NA Excise Taxes ($2,424) ($2,856) NA Gross Profit $17,295 $5,983 $8,570 Adjusted Gross Profit(1) $13,366 $10,157 $7,912 Adjusted Gross Margin(1) 18.2% 46.9% 77.1% Adjusted Gross Margin from Cannabis Operations(1) 36.3% 49.8% 77.1% Three months ended February 28, 2018 Three months ended February 28, 2019
Three months ended November 30, 2018
In thousands of Canadian dollars, unless otherwise noted (1) Non-IFRS measure Note: Aphria Inc. acquired CC Pharma in January 2019 which largely contributed to the increase in distribution revenue.
17
Common Share Outstanding 250,700,023 98.0% Options 4,203,760 1.6% Warrants 1,028,087 0.4% Total Fully Diluted Shares 255,931,870(1) $135 MILLION CASH & NEAR CASH POSITION(2) WORKING CAPITAL $131 MILLION INVENTORY 12,126 KILOGRAMS (OR KILOGRAM EQUIVALENTS)
In Canadian dollars, unless otherwise noted (1) Exercisable and in-the-money. (2) Includes cash and cash equivalents & marketable securities as disclosed in the Management Discussion & Analysis released on April 15, 2019.
As of February 28, 2019 As of April 12, 2019
18
AFRICA:
Lesotho: JV and off-take agreement with Verve Dynamics
SOUTH AMERICA:
Acquisition of LATAM Holdings Inc., providing access to Colombia, Argentina, Jamaica Paraguay: Signed LOI for exclusive supply agreement with Insumos Medicos, S.A., to provide medical cannabis
PAN ASIA:
Australia: 25% ownership of public licensed producerAlthea Supply agreement for clinical drug trials with MedLab and one other company
NORTH AMERICA:
Canada: Supply agreements with every Canadian province and the Yukon Territory, strategic partnerships establishing wholesale supply agreements
EUROPE:
Germany: Acquired CC Pharma with access to over 13,000 pharmacies; one of only 3 cultivation licenses Italy: One of only 7 cannabis import licenses Malta: Owns ASG Pharma, a high-capacity lab
19
Net Revenue $73,582 $21,668 $10,267 Gross Profit $17,295 $5,983 $8,570 Fair Value Adjustment on Sale of Inventory(1) $5,542 $8,328 $3,443 Fair Value Adjustment on Biological Assets(2) ($9,471) ($4,154) ($4,101) Adjusted Gross Profit $13,366 $10,157 $7,912 Adjusted Gross Margin 18.2% 46.9% 77.1% Three months ended February 28, 2018 Three months ended February 28, 2019
Three months ended November 30, 2018
In thousands of Canadian dollars, unless otherwise noted (1) Fair value adjustment on sale of inventory is part of the Company’s cost of sales due to IFRS standards relating to agriculture and biological assets (i.e. living plants or animals). This line item represents the effect of the non-cash fair value adjustment of inventory sold in the period. (2) Fair value adjustment on growth of biological assets is part of the Company’s cost of sales due to IFRS standards relating to agriculture and biological assets (i.e. living plants or animals). This line item represents the effect of the non-cash fair value adjustment of biological assets (medical cannabis) produced in the period.
Reconciliation of IFRS Gross Profit to Adjusted Gross Profit
20
Revenue from Cannabis Produced $17,862 $22,738 $10,267 Excise Taxes ($2,424) ($2,856) NA Cannabis Net Revenue $15,983 $19,882 $10,267 Productions Costs ($10,175) ($9,971) ($2,355) Adjusted Gross Profit from Cannabis Operations $5,808 $9,911 $7,912 Adjusted Gross Margin from Cannabis Operations 36.3% 49.8% 77.1% Three months ended February 28, 2018 Three months ended February 28, 2019
Three months ended November 30, 2018
In thousands of Canadian dollars, unless otherwise noted
Reconciliation from Revenue from Cannabis Produced to Adjusted Gross Profit from Cannabis Operations